Janssen Outlines Plan to Overturn $70M Risperdal Verdict
- Last Updated: July 27th, 2023
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Janssen Outlines Plan to Overturn $70M Risperdal Verdict
In an attempt to overturn the largest award thus far to come out of the Risperdal mass tort program in Philadelphia, Janssen Pharmaceuticals has filed a list of alleged errors it contends that the trial court made during the A.Y. v. Janssen Pharmaceuticals case.
The October 12th filing contested the adequacy of the evidence on several points, charging that the court improperly limited Janssen’s ability to describe the benefits of Risperdal to the jury and challenging the $750,000 damages cap that the court applied to the case.
The case was the fifth lawsuit to be tried of the Risperdal mass tort program.
All the Risperdal cases make similar allegations, including charges that Janssen failed to properly warn that use of the drug caused male adolescent patients to grow female breasts (a condition known as gynecomastia), suffer psychological trauma, and in many cases required surgery to remove the breast tissue.
Table of Contents
What is Risperdal?
Risperdal is an anti-psychotic drug that was first approved by the FDA in 1993 to treat schizophrenia in adults.
The FDA later expanded approval of the drug to treat irritability in children and adolescents that were directly related to autism.
It has since also been approved to treat acute mania and bipolar disorders in younger patients.
Physicians have also commonly prescribed Risperdal off-label to treat other disorders among young patients, including attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
Risperdal Lawsuits Continue to Be Filed
As more young patients began taking Risperdal, concerns began to grow about the drug’s potential side effects, which for some patients can persist long after the drug is discontinued.
Risperdal lawsuits are being brought by males who claim that their prescription caused them to develop gynecomastia – enlarged breasts in men.
Since many of these young men are still not of legal age, the timing of the filing of these Risperdal lawsuits are not as strict and we anticipate that more of these lawsuits will continue to move through the courts.
Risperdal Side Effects
- Increased mortality among elderly patients
- Abnormal breast growth in young men, known as gynecomastia
- Diabetes
- Movement disorders
- Neuroleptic malignant syndrome (NMS), a relatively rare but potentially fatal neurological condition
- Parkinsonism, including tremors and difficulty with movement and balance
While gynecomastia is not usually medically dangerous for young men, the psychological effects can be devastating.
A study published in the Plastic Reconstructive Surgery journal in 2013 concluded that gynecomastia has a significant psychosocial impact on adolescent patients that affects their self-esteem, mental health, and ability to function socially.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
